Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment [3]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 92-94

  Kyriazis, Ioannis A ^a   Korovesis, Konstantinos ^a   Bashir, Sidahmed ^a   Liakouras, Andreas ^a   Partheniou, Christos ^a  

^a GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; AGITATION; AKATHISIA; ANAMNESIS; APPETITE DISORDER; BODY MASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG INDUCED DISEASE; DYSKINESIA; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; INSULIN RESISTANCE; LABORATORY TEST; LETTER; MALE; METABOLIC DISORDER; PARKINSONISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIABETIC DIET; DIABETIC KETOACIDOSIS; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 31544438011     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000196116.78129.86     Document Type: Letter

References (14)

1. Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medication. Diabetes Technol Ther. 2003;5:669-683.
2. Goldstein LE, Sporn J, Brown S. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438-443.
3. Casey D. Weight gain and glucose metabolism with atypical antipsychotics. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; December 12-16, 1999; Acapulco, Mexico.
4. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903-912.
5. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes, findings from a large health plan database. J Clin Psychiatry. 2002;63(10):920-930.
6. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics, an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14(1):59-64.
7. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312-314.
8. Nastrallah H. A review of the effect of atypical antipsychotics on weight. PNEC. 2003;28:83-96.
9. Melkersson KI, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
10. Lean EJM, Pajonk FG. Patients on atypical antipsychotic drugs. Diabetes Care. 2003;26(5):1597-1605.
11. Atmaca M, Kuloglu M, Tezcan E, et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res (Netherlands). March 1, 2003;60(1):99-100.
12. Wirshing DA, Spellburg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778-783.
13. Gatta B, Rigalleu V, Gin H. Diabetic keto-acidosis with olanzapine treatment. Diabetes Care. 1999;6:435-436.
14. Monvale NJ. Zyprexa (olanzapine). In Physician's Desk Reference. Med Econ. 1998:1512-1518.